Ifp Advisors, Inc Geron Corp Transaction History

Ifp Advisors, Inc

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Sep 06, 2022	BUY	$1.19 - $1.65 $357 - $495	300 New	300 $1,000
Q2 2022 Aug 12, 2022	SELL	$1.19 - $1.65 $357 - $495	-300 Closed	0 $0
Q1 2022 Sep 06, 2022	BUY	$0.99 - $1.6 $297 - $480	300 New	300 $0
Q4 2021 Jan 12, 2022	SELL	$1.22 - $1.72 $10,370 - $14,620	-8,500 Closed	0 $0
Q1 2021 Apr 30, 2021	SELL	$1.52 - $2.1 $614 - $848	-404 Reduced 4.54%	8,500 $14,000
Q4 2020 Jan 25, 2021	SELL	$1.55 - $2.05 $923 - $1,221	-596 Reduced 6.27%	8,904 $15,000
Q2 2020 Aug 05, 2020	BUY	$1.05 - $2.18 $2,100 - $4,360	2,000 Added 26.67%	9,500 $20,000
Q3 2019 Nov 07, 2019	BUY	$1.15 - $1.59 $8,625 - $11,925	7,500 New	7,500 $10,000
Q1 2019 May 15, 2019	SELL	$1.01 - $1.83 $7,777 - $14,091	-7,700 Closed	0 $0
Q4 2018 Jan 23, 2019	SELL	$0.98 - $1.85 $28,175 - $53,187	-28,750 Reduced 78.88%	7,700 $7,000
Q3 2018 Oct 25, 2018	SELL	$1.76 - $6.38 $2,335 - $8,466	-1,327 Reduced 3.51%	36,450 $0
Q2 2018 Aug 07, 2018	BUY	$3.29 - $4.82 $34,666 - $50,788	10,537 Added 38.68%	37,777 $0
Q1 2018 Jun 03, 2019	SELL	$1.81 - $5.98 $2,763 - $9,131	-1,527 Reduced 5.31%	27,240 $49,000
Q1 2018 May 09, 2018	BUY	$1.81 - $5.98 $2,763 - $9,131	1,527 Added 5.61%	28,767 $0
Q4 2017 Jan 24, 2018	SELL	$1.8 - $2.32 $11,039 - $14,228	-6,133 Reduced 18.38%	27,240 $0
Q3 2017 Oct 30, 2017	BUY	$1.99 - $2.65 $264 - $352	133 Added 0.4%	33,373 $73,000
Q2 2017 Jun 03, 2019	SELL	N/A	-1,500 Reduced 4.32%	33,240 $92,000
Q4 2016 Jun 03, 2019	SELL	N/A	-100 Reduced 0.29%	34,740 $72,000
Q2 2016 Jun 03, 2019	BUY	N/A	34,840	34,840 $93,000

275

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.51B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.